Fernando J. Bravo

General Practice
Arecibo, PR 00612

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

Identification and engineering of potent bispecific antibodies that protect against herpes simplex virus recurrent disease.

Identification and engineering of potent bispecific antibodies that protect against herpes simplex virus recurrent disease.

Journal: Cell reports
Published: February 12, 2025

Intermittent therapy with helicase-primase inhibitor IM-250 efficiently controls recurrent herpes disease and reduces reactivation of latent HSV.

Intermittent therapy with helicase-primase inhibitor IM-250 efficiently controls recurrent herpes disease and reduces reactivation of latent HSV.

Journal: Antiviral research
Published: August 25, 2023

Selection, activity, and nuclease stabilization of cross-neutralizing DNA aptamers targeting HSV-1 and HSV-2.

Selection, activity, and nuclease stabilization of cross-neutralizing DNA aptamers targeting HSV-1 and HSV-2.

Journal: Virology
Published: July 30, 2023

Immunisation Using Novel DNA Vaccine Encoding Virus Membrane Fusion Complex and Chemokine Genes Shows High Protection from HSV-2.

Immunisation Using Novel DNA Vaccine Encoding Virus Membrane Fusion Complex and Chemokine Genes Shows High Protection from HSV-2.

Journal: Viruses
Published: September 30, 2022

Cross protective efficacy of the Non-Neurotropic live attenuated herpes simplex virus type 1 vaccine VC-2 is enhanced by intradermal vaccination and deletion of glycoprotein G.

Cross protective efficacy of the Non-Neurotropic live attenuated herpes simplex virus type 1 vaccine VC-2 is enhanced by intradermal vaccination and deletion of glycoprotein G.

Journal: Vaccine
Published: June 17, 2022

A helicase-primase drug candidate with sufficient target tissue exposure affects latent neural herpes simplex virus infections.

A helicase-primase drug candidate with sufficient target tissue exposure affects latent neural herpes simplex virus infections.

Journal: Science translational medicine
Published: November 24, 2020

The R2 non-neuroinvasive HSV-1 vaccine affords protection from genital HSV-2 infections in a guinea pig model.

The R2 non-neuroinvasive HSV-1 vaccine affords protection from genital HSV-2 infections in a guinea pig model.

Journal: NPJ vaccines
Published: March 02, 2020

A vaccine containing highly purified virus particles in adjuvant provides high level protection against genital infection and disease in guinea pigs challenged intravaginally with homologous and heterologous strains of herpes simplex virus type 2.

A vaccine containing highly purified virus particles in adjuvant provides high level protection against genital infection and disease in guinea pigs challenged intravaginally with homologous and heterologous strains of herpes simplex virus type 2.

Journal: Vaccine
Published: July 11, 2019

Intranasal nanoemulsion-adjuvanted HSV-2 subunit vaccine is effective as a prophylactic and therapeutic vaccine using the guinea pig model of genital herpes.

Intranasal nanoemulsion-adjuvanted HSV-2 subunit vaccine is effective as a prophylactic and therapeutic vaccine using the guinea pig model of genital herpes.

Journal: Vaccine
Published: June 24, 2019

Successful application of prime and pull strategy for a therapeutic HSV vaccine.

Successful application of prime and pull strategy for a therapeutic HSV vaccine.

Journal: NPJ vaccines
Published: March 04, 2019

Duration of protection from live attenuated vs. sub unit HSV-2 vaccines in the guinea pig model of genital herpes: Reassessing efficacy using endpoints from clinical trials.

Duration of protection from live attenuated vs. sub unit HSV-2 vaccines in the guinea pig model of genital herpes: Reassessing efficacy using endpoints from clinical trials.

Journal: PloS one
Published: November 16, 2018

The HSV-1 live attenuated VC2 vaccine provides protection against HSV-2 genital infection in the guinea pig model of genital herpes.

The HSV-1 live attenuated VC2 vaccine provides protection against HSV-2 genital infection in the guinea pig model of genital herpes.

Journal: Vaccine
Published: July 23, 2018
Showing 1-12 of 17

Last Updated: 09/26/2026